Tag: <span>cell line development</span>

Spinning Out: From Concept to Actualization

ExpreS2ion, established in January 2010, is located in the Hørsholm Science Park, north of Copenhagen. It was formed as a spin-out from Affitech A/S (Affitech) which holds an equity position in the company. ExpreS2ion operates as a contract research organization (CRO) offering services related to vector and cell line development, cloning, upstream development, optimization, and production of GLP material using its S2 (Drosophila Schneider 2) cell-based ExpreS2 platform. Two of the company’s founders, Drs. de Jongh and Dyring, and early employees of ExpreS2ion were colleagues for many years at Affitech and Pharmexa A/S (Pharmexa) before the two companies combined. It was during this period that they developed and optimized a S2 expression system for use in the production of therapeutic vaccines. ExpreS2ion’s proprietary protein expression platform, ExpreS2, consists of high-yielding expression vectors, a S2 cell line that grows to higher cell densities than standard S2 cells, an optimized culture media, and a highly efficient transfection reagent specifically optimized for S2 cells…

Read MoreSpinning Out: From Concept to Actualization

Biologics Production

cell line development drosophila s2 drosophila schneider 2 glp material life sciences protein expression therapeutic vaccines therapeutics vaccine production vectors

Streamline Your Cell Line Screening: With the Automated, Microscale, Stirred Tank, Single-Use Bioreactor

The price per patient for protein-based and monoclonal antibody (mAb) therapies runs into thousands of dollars per patient each year. These therapies cost considerably more to manufacture than small molecules. Hence, if mammalian or insect cell lines expressing high protein titres can be selected and optimized for protein expression using microscale bioreactor models early in development, then manufacturing costs can be reduced significantly…

Read MoreStreamline Your Cell Line Screening: With the Automated, Microscale, Stirred Tank, Single-Use Bioreactor

Analytics Biologics Biologics Production Cell Lines Manufacturing Process Automation Regulatory

ambr15 benchtop bioreactor mimic cell line development cell line screening mab media development microbioreactor monoclonal antibody Process Automation sartorius stirred tank

Expression Vector Engineering for Cell Line Development — New Roles for “Old” Sequences

Expression vector and cell line engineering is the basis for expression and industrial production of biopharmaceuticals. The ultimate goal is to obtain clonal cell lines that secrete the protein of interest with high cell-specific productivity, and at consistently high levels over an extended number of cell generations, allowing for scale-up and cost-efficient large-scale manufacturing. Productivity and stability of expression are thus the prerequisites for developing commercially viable ­processes…

Read MoreExpression Vector Engineering for Cell Line Development — New Roles for “Old” Sequences

Manufacturing

cell line development expression vector engineering intervening sequences protein expression transgene expression

An Alternative Method for the Rapid Generation of Stable, High-Expressing Mammalian Cell Lines

Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that provide benefits such as shorter timelines, improved consistency, higher production, better genetic stability, and increased flexibility. Each of these advantages extends a large cost benefit to companies as their recombinant protein products are moved from development into the clinic and finally to commercial launch. A versatile system has been developed that is capable of transferring genes of interest into a wide variety of mammalian host cells and offers a number of the above advantages over other methods. The system, which is referred to as GPEx™ (an acronym for “gene product expression”), utilizes replication-defective retroviral vectors, derived from Moloney murine leukemia virus (MLV) and pseudotyped with vesicular stomatitis virus G protein (VSV-G), to stably insert single copies of genes into dividing cells…

Read MoreAn Alternative Method for the Rapid Generation of Stable, High-Expressing Mammalian Cell Lines

Biologics Production Viral Vectors

amplification cell line development mammalian cell line development retroviral vector stability

Rapid Development of CHO Cell Lines for High-Level Production of Recombinant Antibodies

Organizations developing biopharmaceuticals are often faced with the challenge of developing, as rapidly as possible, a production system for a recombinant protein or antibody intended for use in clinical trials. For expression of antibodies and other proteins with complex post-translational modifications, Chinese hamster ovary (CHO) cells are often the host of choice. However, isolation of CHO cell lines producing even moderate levels of a protein of interest is usually a lengthy process due to the need for at least one and usually several gene amplification steps. Gene amplification, which is usually accomplished through the dihydrofolate reductase (dhfr)/methotrexate system, is a requirement for most CHO expression vectors because the absolute expression level from each copy of an integrated expression plasmid is generally very low…

Read MoreRapid Development of CHO Cell Lines for High-Level Production of Recombinant Antibodies

Biologics Production

amplification cell line development expression mammalian expression vectors recombinant antibodies recombinant proteins